HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Lee, T.-M. Articles by Chou, T.-F. Search for Related Content PubMed PubMed Citation Articles by Lee, T.-M. Articles by Chou, T.-F.

Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins

¹Department of Internal Medicine, College of Medicine, National Taiwan University, National Taiwan University Hospital; and ²Department of Surgery, Municipal Jen-Ai Hospital, Taipei, Taiwan

Submitted 17 May 2002 ; accepted in final form 5 March 2003

Troglitazone, an antidiabetic thiazolidinedione, has been shown to have a scavenging effect on reactive oxygen species, which can modulate expression of connexin43. The study purpose was to evaluate whether troglitazone provides cardioprotection and to assess whether the cardioprotection is associated with an attenuated expression of connexin43 at the border of infarction in a canine model of acute myocardial infarction. Vehicle or troglitazone (1, 5, and 50 mg/kg; n = 14 for each group) was given intravenously 15 min before the coronary artery occlusion. Among the survivors, infarct size was significantly larger in the control than in the supplemented groups. There was a significantly lower infarct size in the high-dose group compared with that in the low-dose group (15 ± 7% vs. 23 ± 10% of the risk region in the low-dose group, P = 0.04). Reperfusion caused a significant elevation in superoxide anions as measured by lucigenin-derived chemiluminescence, which was significantly inhibited in animals treated with troglitazone. Connexin43 underwent dephosphorylation in response to ischemia-reperfusion measured by Western blot in control hearts at the border zone; these changes were significantly enhanced by troglitazone administration. Confocal microscopy confirmed the changes of junctional complexes. The magnitude of infarct size positively correlated with the magnitude of phosphorylated connexin43 expression assessed by Western blot analysis (r = 0.73, P < 0.0001). This result demonstrated that the cardioprotective effect of troglitazone as an antioxidant may be associated with reduced phosphorylation of myocardial connexin43 protein.

acute myocardial infarction; contraction band necrosis; reperfusion

This article has been cited by other articles:

				A. L. Wit and H. S. Duffy Drug development for treatment of cardiac arrhythmias: targeting the gap junctions Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H16 - H18. [Full Text] [PDF]

				Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al. PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323. [Abstract] [Full Text] [PDF]

				H.-R. Liu, L. Tao, E. Gao, B. L Lopez, T. A Christopher, R. N Willette, E. H Ohlstein, T.-L. Yue, and X.-L. Ma Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovasc Res, April 1, 2004; 62(1): 135 - 144. [Abstract] [Full Text] [PDF]